Affiliate disclosure: Some links in this article are affiliate links. We may earn a commission at no additional cost to you.

Medical disclaimer: This article is for informational purposes only. It is not medical advice, diagnosis, or treatment. Not medical advice. Consult a qualified healthcare professional before changing your diet, exercise, or supplement regimen.

A cluster of fisetin clinical trials registered between 2020 and 2024 are reaching their expected data windows in 2025 and 2026. That matters for a supplement category where nearly all of the public attention — including the 2017 Mayo Clinic polyphenol screening study and the 2018 Yousefzadeh EBioMedicine paper that established fisetin’s reputation in aging biology — came from preclinical work. The question researchers and practitioners following this field have been waiting to address is whether fisetin’s documented senolytic activity in mouse models produces measurable changes in human senescent cell burden markers. Early-phase data has started to arrive, and the picture it presents is more specific than the original headlines suggested — and considerably more calibrated.

For background on what the foundational Mayo Clinic research established and how fisetin compares to other natural senolytic candidates: the fisetin senolytic evidence article covers that in full. For supplement buying specifics — pulsed dosing rationale, bioavailability considerations, brand comparison — the fisetin supplement buying guide covers that separately. This article addresses specifically what has shifted in 2025-2026 and what that update means for someone tracking this research.

The fisetin trial cohort reaching its data window

The registered fisetin Phase 1-2 human trial landscape has expanded considerably from the two Mayo Clinic trials (NCT02848131, NCT02652052) that were underway as of 2022. By 2024, ClinicalTrials.gov showed multiple Phase 1-2 fisetin studies in different patient populations and contexts — trials in older adults with physical function limitations, studies examining fisetin in cognitive aging contexts (including NCT04784702 and related registrations), and investigations designed to establish target engagement: does orally administered fisetin at specific doses produce detectable changes in human tissue and plasma senescent cell markers?

The shared design logic across this cohort of trials reflects what Phase 1-2 work in senolytics is actually trying to establish: not whether a compound extends lifespan, but whether it demonstrably engages the proposed mechanism in living human biology. For fisetin, the relevant targets are biomarkers associated with cellular senescence — p16^INK4a expression in tissue samples, circulating SASP components including IL-6, IL-1β, and PAI-1, and other molecular indicators. Positive Phase 2 target engagement means fisetin administration at a tested protocol produced detectable changes in these markers compared to placebo or baseline in the study population. That is the question these trials were designed to answer, and it is genuinely distinct from clinical efficacy claims.

The status through mid-2026: several of these trials have reached completion or near-completion according to their ClinicalTrials.gov registered timelines. The published literature on fisetin-specific human trial results remains limited. The broader senolytic research landscape in 2025-2026 — covered in journals including Nature Aging and Aging Cell — has moved toward human biomarker data across multiple senolytic candidates and related cellular aging interventions. Where early-phase fisetin-relevant data has appeared in this literature, the directional findings align with preliminary target engagement signals rather than clinical outcome evidence. Researchers and the journals they publish in have been consistent about this framing: the phrase “promising preliminary evidence” is doing real work in these papers, not functioning as boilerplate.

What Phase 1-2 target engagement data actually establishes

The distance between “fisetin shows target engagement in Phase 2 human biomarker studies” and “fisetin should be taken as a longevity supplement” is wider than most coverage of this research suggests. Understanding why matters for reading any subsequent updates on this trial cohort.

Target engagement at Phase 1-2 means the compound does something measurable in the human body at the dose and timing tested. A positive finding means the researchers observed statistically meaningful changes in the molecular targets — the senescent cell biomarkers — compared to the control condition, in the study population at the doses used. That is informative. It establishes that the compound is pharmacologically active in humans at the doses studied, not only in cell culture or rodents.

What it does not establish: whether those biomarker changes translate to outcomes that a patient cares about — improved physical function, reduced disease incidence, extended years of good health. Establishing that requires larger randomized controlled trials with clinical endpoints, statistical power adequate to detect meaningful differences, and follow-up periods long enough for functional outcomes to materialize. In the senolytic field, those trials are still being designed and funded on the basis of what Phase 1-2 target engagement data shows. The progression path is exactly as structured as it sounds: Phase 1-2 establishes human pharmacological activity → informs powered Phase 2-3 trial design → those trials establish clinical outcome evidence if the signal is strong enough.

The comparison that puts fisetin’s 2026 position in context: dasatinib plus quercetin (D+Q) is the most extensively studied senolytic combination in humans. D+Q’s published Phase 2 data in idiopathic pulmonary fibrosis and diabetic kidney disease showed target engagement signals and some functional improvement signals — enough to justify larger powered trials — but D+Q is not yet a standard-of-care treatment for either condition. Fisetin is meaningfully behind D+Q in the Phase 2 human data stack, while maintaining a stronger comparative preclinical senolytic profile from the 2017 Mayo screening that put it ahead of quercetin in head-to-head cell culture comparisons. The 2026 data has not changed that relative standing, but it has added some human pharmacological data where there was essentially none in 2022.

Japan’s ichigo: the agricultural angle on fisetin’s food history

The link between Japan’s strawberry agriculture and fisetin research is real in food chemistry, but requires honest dose context to avoid misreading.

Strawberries carry the highest known fisetin concentrations of any commonly measured food — approximately 160 micrograms per gram of fresh weight, replicated across multiple independent food composition analyses. Japan’s premium strawberry production is concentrated in Tochigi and Shizuoka prefectures, with cultivars including Tochiotome (とちおとめ, Tochigi’s leading variety since 1996), Benihoppe (静岡), and Amao (あまおう, Fukuoka) representing the dominant commercial output. These varieties are bred for sweetness, size, aroma, and shelf life — not for fisetin content specifically — and systematic fisetin measurements for individual Japanese cultivars have not been published to date.

The dose context: a 100 mg fisetin capsule — the lower end of what commercial supplements provide — corresponds roughly to the fisetin content in 625 grams of fresh strawberries. The doses discussed in clinical trial contexts for senolytic protocols are substantially above 100 mg. Strawberry consumption at realistic per-meal quantities, even in Japan’s premium ichigo market where single Amaou strawberries retail at prices that reflect their status as gift-quality produce, delivers dietary fisetin at levels well below the ranges explored in preclinical senolytic work.

What chronic strawberry and fruit consumption does deliver is a sustained polyphenol intake pattern with a meaningful evidence base of its own. JPHC cohort and Ohsaki cohort research on Japanese dietary patterns has found associations between consistent flavonoid-rich food intake and lower all-cause mortality over multi-decade follow-up — with the standard caveat that cohort studies cannot isolate fisetin’s specific contribution from the broader dietary pattern. Fisetin also appears at lower but measurable concentrations in other foods that recur across traditional Japanese diet patterns: apples, persimmons (kaki), onions (tamanegi), and cucumbers. The aggregate dietary picture differs from a Western diet in fisetin and flavonoid exposure, though by how much, and with what effect, remains observational.

The key distinction: dietary strawberry consumption and fisetin supplementation are not addressing the same potential dose range or the same proposed mechanism. Someone interested in fisetin’s senolytic activity as a periodic high-concentration intervention is asking a different question than someone interested in flavonoid-rich dietary patterns. Japan’s ichigo culture provides genuine cultural and agricultural context for fisetin’s food history. It does not provide dosing support for the supplement question.

What changed in 2026 for someone tracking this research

The practical question for anyone following fisetin: does the 2026 update — more Phase 1-2 trials reaching their data windows, publications appearing in aging research journals — change the calculus on whether to try fisetin supplementation now?

The honest answer is: modestly, in the direction of reduced uncertainty rather than confirmed benefit.

Before the 2025-2026 data windows, the case for fisetin supplementation rested almost entirely on animal models. The 2017 Mayo Clinic comparative polyphenol screen and the 2018 Yousefzadeh mouse study were genuine scientific contributions, but both were preclinical. Starting fisetin supplementation based solely on mouse longevity data meant making a choice in near-complete absence of human pharmacological information.

After early Phase 1-2 data has started to emerge: the case now includes some preliminary human target engagement signals — evidence that fisetin at specific doses is pharmacologically active in human biology at the relevant molecular targets, not only in rodent models. That is a meaningful addition. It does not establish clinical efficacy. It does not establish what dose is needed in humans or what schedule is optimal. It does not establish safety at repeated high-dose protocols over years. But it reduces the largest specific uncertainty in the previous evidence picture: whether the preclinical biology translates to anything observable in humans at all.

For readers following related research in parallel: the quercetin context that sits alongside fisetin — both polyphenols appeared in the 2017 Mayo senolytic screen — is covered in the quercetin and Awaji Island onion senolytic article. The cellular senescence mechanisms underlying all of this research — SASP, p16/p21 signaling, why senescent cell accumulation is considered relevant to healthspan — are in the cellular senescence and senolytics research article. Spermidine, which works through autophagy induction rather than senescent cell clearance, is a structurally non-overlapping approach covered in the spermidine and natto research article.

Supplement options for those who decide to proceed

The commercial fisetin supplement landscape has not changed significantly in 2026. The brands that established strong market positions in 2022-2024 remain the most consistently referenced in practitioner and researcher communities. What the 2026 evidence update changes is that buyers have slightly more human pharmacological context for what “dose” means — though established human protocols derived from peer-reviewed clinical data still do not exist.

Life Extension Fisetin at 125 mg per capsule is among the most consistently referenced products in practitioner discussions. Life Extension publishes lot-specific Certificates of Analysis and is transparent about third-party testing sources. The 125 mg capsule size provides more flexibility for building toward higher dose protocols than 100 mg products. Search Life Extension Fisetin 125mg on Amazon.

Swanson Fisetin at 100 mg per capsule is a lower-priced option from an established supplement company with decades of market history and available third-party documentation. Search Swanson Fisetin 100mg on Amazon.

Double Wood Supplements Fisetin at 100 mg per capsule appears consistently across independent third-party supplement review comparisons at a competitive price point with COA documentation available. Search Double Wood Fisetin on Amazon.

For buyers interested in higher-dose options that sit closer to the pulse-protocol range discussed in clinical trial literature: search fisetin 500mg capsules on Amazon. COA verification from the specific brand matters more in this size range where the market is more variable in quality practices.

For readers interested in the dietary side — Japanese strawberry extract products that deliver dietary fisetin alongside other polyphenol compounds from the whole berry matrix: search Japanese strawberry extract supplement on Amazon. These products represent a different category from isolated fisetin and should be evaluated on their own evidence basis.

Before starting: Fisetin inhibits cytochrome P450 enzymes (CYP3A4, CYP2C9) in preclinical research, which affects the metabolism of many commonly prescribed medications including statins, anticoagulants, calcium channel blockers, and immunosuppressants. It has shown anti-platelet aggregation activity in animal models. It has mild estrogenic activity in cell culture. Anyone on medications metabolized by CYP3A4 or CYP2C9, anyone on anticoagulant or antiplatelet therapy, anyone with hormone-sensitive conditions, anyone in active cancer treatment, and anyone pregnant or nursing should discuss fisetin supplementation with their clinician before starting. The fisetin supplement buying guide covers these interactions and the pulsed dosing question in detail.

The most useful public signal to monitor as more 2026 data arrives: ClinicalTrials.gov registrations for Mayo Clinic fisetin trials (NCT02848131, NCT02652052, and associated identifiers), PubMed searches under “fisetin human” and “senolytic Phase 2,” and Aging Cell and Nature Aging for the journals where early-phase senolytic human data has most frequently appeared.

---

Related: Fisetin, Senescent Cells, and Japanese Strawberries: What the Mayo Clinic Research Actually Shows | Fisetin Supplement Buying Guide: Pulsed Dosing, Bioavailability, and Third-Party Testing | Cellular Senescence and Senolytics: p16/SASP Mechanisms and Japan’s Research Contribution | Quercetin, Awaji Island Onions, and Senolytics

Sources: Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18–28. | Kirkland JL, Tchkonia T. Cellular Senescence: A Translational Perspective. EBioMedicine. 2017;21:21–28. | ClinicalTrials.gov identifiers NCT02848131, NCT02652052, NCT04784702. | Arai Y et al. Dietary intakes of flavonols, flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL cholesterol concentration. J Nutr. 2000.